Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07446855 | Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours | PHASE1 | RECRUITING | 180 | — | — | Mar 17, 2026 | Mar 29, 2030 | May 26, 2026 | 18 | United States, Australia +4 |
To assess the safety and tolerability of AZD4956 monotherapy and in combination with anti-cancer agent(s).
PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participants withdraw from study treatment or receive another anti-cancer therapy prior to progression.
To assess the safety and tolerability of AZD4956 monotherapy and in combination with anti-cancer agent(s).
| Arm | Type | Description |
|---|---|---|
| Module 1 Part A: AZD4956 monotherapy (Dose escalation) | EXPERIMENTAL | Participants will receive AZD4956 as monotherapy at ascending dose levels. |
| Module 2 Part A: AZD4956 + saruparib (Dose escalation) | EXPERIMENTAL | Participants will receive AZD4956 at ascending dose levels in combination with saruparib. |
| Module 2 Part A Optional PD backfill cohort: AZD4956 + saruparib | EXPERIMENTAL | Participants will receive AZD4956 in combination with saruparib. |
| Module 2 Part A Optional PD backfill cohort: Saruparib monotherapy | EXPERIMENTAL | Participants will receive saruparib monotherapy. |
| Module 2 Part A Optional non-PD backfill cohort: AZD4956 + saruparib | EXPERIMENTAL | Participants with metastatic castrate resistant prostate cancer (mCRPC) will receive AZD4956 in combination with saruparib. |
| Module 2 Part B: AZD4956 + saruparib (Dose expansion) | EXPERIMENTAL | Participants will receive AZD4956 in combination with saruparib. |
| Name | Type | Description |
|---|---|---|
| AZD4956 | DRUG | AZD4956 will be administered orally. |
| Saruparib | DRUG | Saruparib will be administered orally. |
Core Inclusion Criteria: * Documented locally advanced or metastatic solid tumour malignancy. * Eastern cooperative oncology group (ECOG) performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to screening and first day of dosing. * Minimum life expectancy ≥ 12 weeks. * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |